<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04214808</url>
  </required_header>
  <id_info>
    <org_study_id>AD-208PK</org_study_id>
    <nct_id>NCT04214808</nct_id>
  </id_info>
  <brief_title>To Evaluate the Pharmacokinetics and Safety of AD-208</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of AD-208</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addpharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Addpharma Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate pharmacokinetics and safety of AD-208.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose is that pharmacokinetics and safety of AD-208 in healthy adult male volunteers
      are evaluated as compared to Avodart Soft Capsule 0.5mg.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2020</start_date>
  <completion_date type="Anticipated">March 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve in time plot (AUCt)</measure>
    <time_frame>Pre-dose(0 hour) to 72 hour</time_frame>
    <description>AUCt of the total ingredient of dutasteride</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose(0 hour) to 72 hour</time_frame>
    <description>Cmax of the total ingredient of dutasteride</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve in time plot (AUCinf)</measure>
    <time_frame>Pre-dose(0 hour) to 72 hour</time_frame>
    <description>AUCinf of the total ingredient of dutasteride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax(Tmax)</measure>
    <time_frame>Pre-dose(0 hour) to 72 hour</time_frame>
    <description>Tmax of the total ingredient of dutasteride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective half-life(t1/2)</measure>
    <time_frame>Pre-dose(0 hour) to 72 hour</time_frame>
    <description>t1/2 of the total ingredient of dutasteride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance(CL/F)</measure>
    <time_frame>Pre-dose(0 hour) to 72 hour</time_frame>
    <description>CL/F of the total ingredient of dutasteride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution(Vd/F)</measure>
    <time_frame>Pre-dose(0 hour) to 72 hour</time_frame>
    <description>Vd/F of the total ingredient of dutasteride</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From Day -1 until Day 59</time_frame>
    <description>Incidence rate of adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>Avodart Soft Capsule 0.5mg to AD-208</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Avodart Soft Capsule 0.5mg, 1 Capsule Period 2: AD-208, 1 tab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD-208 to Avodart Soft Capsule 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: AD-208, 1 tab Period 2: Avodart Soft Capsule 0.5mg, 1 Capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD-208</intervention_name>
    <description>Dutasteride 0.2mg</description>
    <arm_group_label>AD-208 to Avodart Soft Capsule 0.5mg</arm_group_label>
    <arm_group_label>Avodart Soft Capsule 0.5mg to AD-208</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avodart Soft Capsule 0.5mg</intervention_name>
    <description>Dutasteride 0.5mg</description>
    <arm_group_label>AD-208 to Avodart Soft Capsule 0.5mg</arm_group_label>
    <arm_group_label>Avodart Soft Capsule 0.5mg to AD-208</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male Adult aged between 19 to 50 at the time of screening visit

          -  Weight over 50kg and Body mass index (BMI) between 17.5 kg/m2 and 30.5 kg/m2 at the
             time of screening visit

          -  No evidence of medical symptoms or signs of congenital or no chronic disease

        Exclusion Criteria:

          -  If having a clinically significant disease or medical history for blood/tumor,
             genitourinary systen, liver/biliary system, kidney, respiratory system, alimentary
             system, endocrine system, immune system, cardiovascular system, nervous system, skin
             and psychical disorder, etc
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Ran Yoon, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung Tae Kim, D.V.M</last_name>
    <phone>82-31-891-5661</phone>
    <email>ktkim@addpharma.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Ran Yoon, M.D., Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 26, 2019</study_first_submitted>
  <study_first_submitted_qc>December 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 29, 2019</last_update_submitted>
  <last_update_submitted_qc>December 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

